The regulation for the authorization of veterinary medicinal products (VMPs) to the European market requires an environmental risk assessment (ERA). The ERA results are then included in a benefit-risk assessment. However, knowledge and experience in the benefit-risk assessment implementation is developing and current guidelines are vague on how environmental risks and risk mitigation measures (RMMs) are integrated into the benefit-risk assessment process. This study was therefore conducted to develop new approaches and knowledge for the integration of environmental risk assessment into the benefit-risk assessment process. Novel methodologies for the integration of ERA data into the benefit-risk assessment were initially developed. The main ...
Veterinary Medicinal Products (VMPs) are used in intensive aquaculture production to treat a wide ra...
The environmental risk associated with the use of veterinary medicinal products is assessed at regis...
This report contains a proposal for a simplified Phase 1 assessment for immunological veterinary med...
Veterinary medicinal products (VMPs) require, as part of the European Union (EU) authorization proce...
Within EU marketing authorization procedures of human and veterinary medicinal products (HMP and VMP...
Within EU marketing authorization procedures of human and veterinary medicinal products (HMP and VMP...
The EC has issued directives (1981, 1992) requesting for registration of veterinary medicinal produc...
The current and future expansion of aquaculture production appears to be only manageable by using ve...
The current and future expansion of aquaculture production appears to be only manageable by using ve...
An alarming decline of vulture populations (up to 95%) in Pakistan in the late 1990__s has recently ...
Veterinary Medicinal Products (VMPs) are used in intensive aquaculture production to treat a wide ra...
Veterinary Medicinal Products (VMPs) are used in intensive aquaculture production to treat a wide ra...
In this paper, we investigate the applicability of experimental model ecosystems (microcosms and mes...
Veterinary Medicinal Products (VMPs) are used in intensive aquaculture production to treat a wide ra...
Veterinary Medicinal Products (VMPs) are used in intensive aquaculture production to treat a wide ra...
Veterinary Medicinal Products (VMPs) are used in intensive aquaculture production to treat a wide ra...
The environmental risk associated with the use of veterinary medicinal products is assessed at regis...
This report contains a proposal for a simplified Phase 1 assessment for immunological veterinary med...
Veterinary medicinal products (VMPs) require, as part of the European Union (EU) authorization proce...
Within EU marketing authorization procedures of human and veterinary medicinal products (HMP and VMP...
Within EU marketing authorization procedures of human and veterinary medicinal products (HMP and VMP...
The EC has issued directives (1981, 1992) requesting for registration of veterinary medicinal produc...
The current and future expansion of aquaculture production appears to be only manageable by using ve...
The current and future expansion of aquaculture production appears to be only manageable by using ve...
An alarming decline of vulture populations (up to 95%) in Pakistan in the late 1990__s has recently ...
Veterinary Medicinal Products (VMPs) are used in intensive aquaculture production to treat a wide ra...
Veterinary Medicinal Products (VMPs) are used in intensive aquaculture production to treat a wide ra...
In this paper, we investigate the applicability of experimental model ecosystems (microcosms and mes...
Veterinary Medicinal Products (VMPs) are used in intensive aquaculture production to treat a wide ra...
Veterinary Medicinal Products (VMPs) are used in intensive aquaculture production to treat a wide ra...
Veterinary Medicinal Products (VMPs) are used in intensive aquaculture production to treat a wide ra...
The environmental risk associated with the use of veterinary medicinal products is assessed at regis...
This report contains a proposal for a simplified Phase 1 assessment for immunological veterinary med...